Erlotinib Withdrawn Phase 0 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment0
clinicaltrials.gov IdentifierTitleDrugs
NCT02277457Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations